Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?

V. G. Jokubaitis, V. Li, T. Kalincik, G. Izquierdo, S. Hodgkinson, R. Alroughani, J. Lechner-Scott, A. Lugaresi, P. Duquette, M. Girard, M. Barnett, F. Grand'Maison, M. Trojano, M. Slee, G. Giuliani, C. Shaw, C. Boz, J. Haartsen, D. Liew, H. ButzkuevenMSBase Study Group

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)55-56
Number of pages2
JournalMultiple Sclerosis
Volume19
Issue numberSuppl. 11
DOIs
Publication statusPublished - Oct 2013

Keywords

  • fingolimod
  • natalizumab
  • exacerbation

Cite this